NCT00929058已完成不适用
Bevacizumab and Vasoconstriction
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Fore-arm vasomotor response to administered bevacizumab, expressed as percentage change in forearm blood flow ratio
研究概览
简要总结
Rationale: The introduction of angiogenesis inhibitors has remarkably improved treatment of patients with several types of cancer. One of the most common side effects of angiogenesis inhibitors is hypertension. In patients treated with bevacizumab hypertension had an overall incidence up to 32%. The etiology of hypertension caused by treatment with angiogenesis inhibitors is unclear.
Objective: To study if arterial bevacizumab infusion causes acute vasoconstriction using plethysmography in healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Male 18-50 years old
- •normal results of glucose, lipids and creatinine
- •informed consent
排除标准
- •History of abuse of drugs or alcohol
- •History of malignant disease
- •First degree relatives with a history of cancer before the age of 50
- •First degree relatives with a history of premature cardiovascular disease
- •Current use of medication
- •Clinical evidence of cardiac of pulmonary disease
- •Hypertension ( systolic>140mmHg, diastolic >90mmHg)
- •Diabetes mellitus
- •a history of thombosis or a family history of recurrent thrombosis
- •abnormality on ECG
研究组 & 干预措施
Bevacizumab
Experimental
干预措施: Bevacizumab (Drug)
结局指标
主要结局
Fore-arm vasomotor response to administered bevacizumab, expressed as percentage change in forearm blood flow ratio
时间窗: Infusion of bevacizumab during 6 minutes
次要结局
- Correlation between VEGF concentrations in plasma and the vasoconstrictive response to bevacizumab(Infusion of bevacizumab during 6 minutes)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Bevacizumab and Endothelium Dependent VasodilationEndothelial DysfunctionCancerHypertensionNCT01125943Radboud University Medical Center24
已完成
不适用
Bevacizumab and vasoconstrictioelevated blood pressureHypertensie10057166NL-OMON33520niversitair Medisch Centrum Sint Radboud10
终止
2 期
Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the ColonColorectal NeoplasmsNCT00314353NSABP Foundation Inc7
Unknown
2 期
Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)Untreated Advanced Non-Small Cell Lung CancerNCT00254319The Cooper Health System
已完成
2 期
Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast CancerBreast CancerNCT00365417NSABP Foundation Inc45